MultiCASE Inc.
In silico toxicity predictions used for ICH M7 and REACH.
MultiCASE collaborates with the US FDA to create models using statistical and expert rule-based QSAR methodology. These models are built using our software program, CASE Ultra, to evaluate pharmaceutical impurities in accordance with ICH M7. In addition to bacterial mutagenicity, we have models used to assess other toxicological endpoints such as genotoxicity, carcinogenicity, skin sensitization, etc. All our models follow OECD guidelines and can also be used to satisfy the information requirements listed in REACH.